Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern. This episode is organised in collaboration with the EASL DHILI Consortium. Faculty Guruprasad Padur Aithal (Moderator)Paul Hayashi (Faculty)Maribel Lucena (Faculty)Paul...

In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment. Faculty Bogdan Procopet (Moderator)Maria Papp (Faculty)Atoosa Rabiee (Faculty)Thomas Reiberger (Faculty)Related episode EASL Studio...

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission. Faculty Marta Alonso-Peña (Moderator)Kate Jack (Faculty)Marko Korenjak (Faculty)Thomas Marjot (Faculty)Related episode EASL Studio from EASL Congress 2023: United we stand:...

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm. Faculty Bruno Sangro (Moderator)Umberto Cillo (Faculty) Helen Reeves (Faculty)María Reig (Faculty)This EASL...

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs. Faculty Debbie Shawcross (Moderator)Rajiv Jalan (Faculty)Sara Montagnese (Faculty)Elliot Tapper...

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions. Faculty Patrizia Burra (Moderator)Maria Buti (Faculty)Peter Jepsen (Faculty)Shira Zelber-Sagi (Faculty)Related episodes EASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio...

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field. Faculty Aleksander Krag (Moderator)Aftab Ala (Faculty)Pavel Strnad (Faculty)Alice Turner (Faculty)Related episodes EASL Studio from EASL Congress 2023: Clinical trials in rare diseases...

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research? Faculty Paolo Angeli (Moderator)Guadalupe Garcia-Tsao (Faculty)Valérie Paradis (Faculty)Thomas Reiberger (Faculty)Related episodes EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachEASL...

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead. Faculty Thomas Berg (Moderator)Katie Kelley (Faculty)Daniela Sia...

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management. Faculty Pierre-Emmanuel Rautou (Moderator)Virginia Hernández-Gea (Faculty)Patrick Kamath (Faculty)Wim Laleman (Faculty)Related episodes: EASL Studio S2E6:...

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists. Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management! Faculty Sven Francque (Moderator)Willem...

Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health. Faculty Aleksander Krag (Moderator)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.

Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition. This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and...

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice. Faculty Tom Lüdde (Moderator)Christoph Roderburg (Faculty)Anna Saborowski (Faculty)Arndt Vogel...

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions. Faculty Palak Trivedi (Moderator)Amanda Ricciuto (Faculty)Marianne Samyn (Faculty)Christoph Schramm (Faculty)This EASL Studio is...

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis. Faculty Thomas Reiberger (Moderator)Juan Gonzalez-Abraldes (Faculty)Elisa Pose (Faculty)Jonel Trebicka (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input...

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases. Faculty Zobair Younossi (Moderator)Laurent...

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases. Faculty Aleksander Krag (Moderator)Juan Pablo Arab (Faculty)Alexandre Louvet (Faculty)Maru Rinella (Faculty)Related episodes: EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E8: The central role of alcohol and...

Join the faculty as they take a deep dive into hepatitis delta (HDV) to: Shed light on the controversies surrounding this disease.Share their perspectives on the latest and most hotly debated recommendations.Discuss how these new recommendations will shape the future of research and patient care.Faculty Thomas Berg (Moderator)Maurizia Brunetto (Faculty)Ohad Etzion (Faculty)Related episodes: EASL Studio S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first...

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life. This episode was scheduled according to the international calendar for the World Food Day (16 October) Faculty Shira Zelber Sagi (Moderator)Riccardo Dalle Grave (Faculty)Giulio Marchesini (Faculty)Related episodes EASL Studio S4E8: The central...

This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research. Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than...

In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article: Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?What are the main issues regarding the measurement and thresholds for MRFs?Is the introduction of the MetALD category clinically justified?Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be...

This EASL Studio episode covers the highlights of the SLD Summit 2023, including: Physiopathological mechanismProblems encountered in the cirrhotic stage in SLDNovelties about liver biopsiesFaculty Sven Francque (Moderator)Quentin Anstee (Faculty)Frank Tacke (Faculty)Maja Thiele (Faculty)Related episodes EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio Live from EASL Congress 2023: Steatotic liver disease global...

Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). HEV infections are among the most common causes of acute hepatitis worldwide. 2 different settings: HEV genotypes 1 and 2 cause primarily in water-born outbreaks inn resource-limited settingsHEV genotypes 3 and 4 have emerged as porcine zoonoses in middle and high-income areas, including EuropeThis Studio focuses on Zoonotic Hep E, especially HEV Genotype 3 infection and discusses recent...